Concurrence of Stevens-Johnson syndrome and bilateral parotitis after minocycline therapy

Case Reports in Dermatology

Volumn 2, Issue 2, 2010, Pages 88-94

  Yoon, Jimi ^a   Lee, Seung Hun ^a   Kim, Tae Heung ^a,c   Choi, Deok Jin ^a,c   Kim, Jin Pyeong ^b   Yoon, Tae Jin ^a  

^a Gyeongsang National University   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

^c White Skin Clinic   (South Korea)

Author keywords

Minocycline; Parotitis; Stevens Johnson syndrome

Indexed keywords

MINOCYCLINE; MUMPS VACCINE;

ADOLESCENT; ARTICLE; BACTERIUM CULTURE; BLOOD SAMPLING; BODY SURFACE; CHEEK; CONJUNCTIVITIS; ECHOGRAPHY; FEVER; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MALE; MOUTH LESION; MUMPS; ODYNOPHAGIA; PAROTITIS; PRIORITY JOURNAL; SKIN DEFECT; SPUTUM ANALYSIS; STEVENS JOHNSON SYNDROME; URINALYSIS;

EID: 79951991729     PISSN: None     EISSN: 16626567     Source Type: Journal    
DOI: 10.1159/000314952     Document Type: Article

References (14)

1. Shapiro LE, Knowles SR, Shear NH: Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997;133:1224-1230. (Pubitemid 27443814)
2. Auqier-Dunant A, Mockenhaupt M, Naldi L, et al: Correlation between clinical patterns and causes of erythema multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2002;138:1019-1024.
3. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC: Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-96.
4. Shoji A, Someda Y, Hamada T: Stevens-Johnson syndrome due to minocycline therapy. Arch Dermatol 1987;123:18-20. (Pubitemid 17130449)
5. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al: Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44. (Pubitemid 350249390)
6. Roujeau J: Clinical heterogeneity of drug hypersensitivity. Toxicol 2005;209:123-129.
7. Thompson DF: Drug-induced parotitis. J Clin Pharm Ther 1993;18:255-258.
8. Speed BR, Spelman DW: Sialadenitis and systemic reaction associated with phenylbutazone. Aust N Z J Med 1982;12:261-264. (Pubitemid 12050186)
9. Vidal PC, González QA: Doxycycline-induced parotitis. Postgrad Med J 1991;67:313-314.
10. Mirsky S: Salivary gland reaction to phenylbutazone. CMAJ 1970;102:91-104.
11. Garfunkel AA, Roller NW, Nichols C, Ship II: Phenylbutazone-induced sialadenitis. Oral Surg Oral Med Oral Pathol 1974;38:223-226.
12. Rosen DH: Acute parotitis associated with depression and psychoactive drug therapy. Compr Psychiatry 1973;14:183-188.
13. Goulden V, Glass D, Cunliffe WJ: Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996;134:693-695. (Pubitemid 26120737)
14. Sturkenboom MC, Meier CR, Jick H, Stricker BH: Minocycline and lupus-like syndrome in acne patients. Arch Intern Med 1999;159:493-497. (Pubitemid 29108915)